Pipeline

One molecule, four programs

Every Adjuvia program is built on one proprietary form of astaxanthin, with mitochondrial-repair, anti-inflammatory and cell-regenerative properties. We are advancing two programs ourselves and offering two to partners.

Programs at a glance

Advancing ourselves

  • ATI-105

    Friedreich’s ataxia

    Lead indication · Phase 1 enrolling

    NextPhase 1 SAD/MAD completeQ3 2027

  • ATI-105

    Leigh syndrome & other primary mitochondrial diseases

    IND-enabling

    NextIND submissionQ2 2028

  • ATI-108

    IVF / assisted reproduction

    Culture-media additive †

    NextFDA INTERACT meetingQ2 2027

Available for partnership

  • ATI-106

    Alzheimer’s disease

    EGCG nanoparticle

    NextPreclinical Data PackageYE 2026

  • ATI-107

    LNP delivery for vaccines, immunotherapies and nucleic-acid medicines

    Inflammation-blocking LNP

    NextIND-enabling studiesYE 2026

† ATI-108 is an additive for IVF culture media and follows a different regulatory path from a drug; its position on the chart is approximate.

Advancing ourselves

Programs we’re developing

ATI-105 · Rare mitochondrial disease · Phase 1

Repairing the mitochondria behind inherited disease

An oral lipid nanoparticle form of astaxanthin for inherited mitochondrial diseases. Our Phase I trial in healthy volunteers begins dosing October 2026, with FA patients enrolling later in 2027, and Leigh Syndrome and other primary mitochondrial diseases planned next.

Explore the Science

ATI-108 · IVF and assisted reproduction · IND-Enabling

Healthier eggs for IVF

Every human egg carries some 600,000 mitochondria. When they are damaged, egg quality falls, embryos struggle and IVF cycles fail.

ATI-108 brings our astaxanthin into IVF culture media in a water-dispersible lipid nanoparticle, to repair the mitochondria in eggs and protect embryos from damage when it matters most. It began with our fish, which kept breeding years past their prime.

~600,000

mitochondria in every human egg

Contact us about ATI-108

Available for partnership

Ready for a development partner

Full data packages are available under CDA.

ATI-106 · Alzheimer’s disease

Getting EGCG into the brain

EGCG, a compound from green tea, breaks up the amyloid plaques and tau tangles linked to Alzheimer’s. On its own it is poorly absorbed and can’t cross the blood-brain barrier. In preclinical studies, our lipid nanoparticle carried it into the brain after a single oral dose.

Partnering details

ATI-107 · Inflammation-Blocking LNP-Nucleic Acid Delivery

Less inflammatory LNP delivery

Lipid nanoparticles carry mRNA and gene medicines, but they can set off harmful inflammation. ATI-107 is designed to block that inflammatory response while still delivering the payload broadly to multiple organs.

Partnering details

For patients and families

Friedreich’s ataxia and our clinical trial

Learn the Science

For partners

Programs and platform capabilities open for partnership

Partnering